Dose Response of Epinephrine - Trial NCT02692313
Access comprehensive clinical trial information for NCT02692313 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by University of Maryland, Baltimore and is currently Recruiting. The study focuses on Diabetes Complications. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Maryland, Baltimore
Timeline & Enrollment
Early Phase 1
Jun 01, 2016
Feb 01, 2024
Primary Outcome
Flow mediated dilation (FMD) of the brachial artery
Summary
Epinephrine is the principal physiologic defense against hypoglycemia in type 1 and longer
 duration type 2 DM. Despite this, it is unknown how epinephrine regulates in-vivo endothelial
 function and atherothrombotic balance in humans. The specific aim of our study will be to
 determine the dose response effects of the key ANS counterregulatory hormone epinephrine on
 endothelial function, fibrinolytic balance and pro-atherogenic inflammatory mechanisms in
 healthy humans.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02692313
Non-Device Trial